Ovid Therapeutics Inc. (OVID)
| Market Cap | 225.53M |
| Revenue (ttm) | 221.00M |
| Net Income (ttm) | 121.76M |
| Shares Out | 67.82M |
| EPS (ttm) | 1.81 |
| PE Ratio | 1.85 |
| Forward PE | 1.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,659 |
| Open | 3.33 |
| Previous Close | 3.37 |
| Day's Range | 3.30 - 3.43 |
| 52-Week Range | 2.25 - 6.98 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 4.75 (+42.2%) |
| Est. Earnings Date | Nov 11, 2021 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-lik...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 42.22% from the latest price.
News
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological dis...
A Trio of Magic Formula Stock Picks
In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
Dr. Michael Poole to Join the Board of Directors
Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neur...
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a ...
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions
Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The com...
4 Biotech Penny Stocks To Watch That Are Heating Up This Month
Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...
OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today
Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocket...
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Chi...
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today
Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. The post Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today appear...
Why Ovid Therapeutics Stock Is Imploding Today
The company reported disappointing results from a late-stage clinical trial.
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Me...
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical develop...
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virt...
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...